Logo

NAUT

Nautilus Biotechnology, Inc.

NAUT

Nautilus Biotechnology, Inc. • NASDAQ
$2.25 ▼ -0.88% (-0.02)
Market Cap $284.19 M
52w High $2.54
52w Low $0.62
Dividend Yield 0%
P/E -4.5
Volume 114.81K
Outstanding Shares 126.31M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $13.853M ▼ $-13.574M ▲ 0% $-0.11 ▲ $-11.955M ▲
Q2-2025 $0 $15.464M ▼ $-15.033M ▲ 0% $-0.12 ▲ $-13.4M ▲
Q1-2025 $0 $17.219M ▲ $-16.613M ▲ 0% $-0.13 ▲ $-14.988M ▼
Q4-2024 $0 $13.627M ▼ $-17.594M ▼ 0% $-0.14 ▼ $-11.241M ▲
Q3-2024 $0 $17.488M $-16.446M 0% $-0.13 $-14.834M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $131.427M ▼ $200.915M ▼ $31.776M ▼ $169.139M ▼
Q2-2025 $147.873M ▲ $213.189M ▼ $32.095M ▼ $181.094M ▼
Q1-2025 $138.81M ▲ $227.69M ▼ $33.255M ▼ $194.435M ▼
Q4-2024 $129.893M ▼ $242.743M ▼ $34.013M ▼ $208.73M ▼
Q3-2024 $140.609M $259.704M $36.27M $223.434M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-13.574M ▲ $-11.034M ▲ $452K ▼ $0 ▼ $-10.582M ▼ $-11.452M ▲
Q2-2025 $-15.033M ▲ $-13.35M ▲ $14.474M ▼ $95K ▲ $1.219M ▼ $-13.746M ▲
Q1-2025 $-16.613M ▲ $-13.937M ▲ $19.511M ▼ $18K ▼ $5.592M ▼ $-14.156M ▲
Q4-2024 $-17.594M ▼ $-14.309M ▼ $37.106M ▲ $440K ▲ $23.237M ▲ $-14.563M ▼
Q3-2024 $-16.446M $-13.113M $-7.503M $140K $-20.476M $-13.822M

Five-Year Company Overview

Income Statement

Income Statement Nautilus is still in the pre-revenue stage, so its income statement is entirely about costs, not sales. The company has been posting steady losses each year, largely driven by research and development and the build‑out of its platform. These losses have grown gradually but not explosively, which suggests reasonably controlled spending for a company trying to develop a new technology. Until commercial launch, results will continue to reflect investment and burn rather than business performance.

Balance Sheet

Balance Sheet The balance sheet shows a development‑stage company with a meaningful cash and asset base relative to its size, supported by positive shareholders’ equity. Debt is present but modest, so the capital structure is not heavily leveraged. Over time, equity has been eroded by ongoing losses, which is normal for a pre‑commercial biotech but still a key watch point. The company has some financial cushion today, but if commercialization is delayed or costs rise, it may eventually need additional capital to replenish that cushion.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting regular spending on people, labs, and technology without any offsetting revenue yet. Free cash flow closely mirrors operating cash flow, because the company has not been investing heavily in large physical assets. This pattern is typical for a platform biotech company still in development mode. The disclosed runway into the later part of the decade provides time, but progress toward launch will need to track reasonably well with this burn profile to avoid financing pressure.

Competitive Edge

Competitive Edge Nautilus is aiming to carve out a new category in proteomics with single‑molecule protein analysis, which, if it works as intended, could be a step change versus traditional tools. Its edge rests on a mix of novel technology, a growing patent portfolio, and early relationships with major pharma and research groups. The ability to generate unique, large‑scale protein data and improve algorithms over time could create a data‑driven moat. At the same time, the platform is not yet commercial, and established methods and competitors have deep customer bases, so Nautilus’s true market position will only become clear once systems are in users’ hands.

Innovation and R&D

Innovation and R&D Innovation is the core of Nautilus’s story. The company is pursuing a highly ambitious single‑molecule proteomics platform built around iterative mapping, machine learning, and custom reagents, aiming to see protein detail that current tools miss. Work on complex targets such as Tau proteoforms in brain tissue shows the kind of high‑value applications it hopes to enable. The roadmap includes an early‑access phase followed by a full commercial launch later in the decade, so sustained, efficient R&D execution and hitting technical milestones on time are critical and remain a key uncertainty.

Summary

Nautilus is a classic early‑stage biotech platform story: no revenue yet, steady cash burn, and a balance sheet that currently supports a multi‑year development window. The potential upside comes from a differentiated technology that could reshape proteomics workflows and deepen understanding of disease biology, supported by patents and notable partnerships. The main risks center on execution: proving the platform works at scale, converting scientific interest into paying customers, managing timelines to launch, and controlling cash usage. Overall, this is a high‑risk, high‑uncertainty situation where future value will depend heavily on scientific validation, product adoption, and access to capital as the company moves from concept to commercial reality.

NEWS

November 3, 2025 · 8:00 AM UTC

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

Read more